BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.87
−2.09%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.81
From 52W high−50.53%
Volume7361.00
Market cap$9.31M
P/E (TTM)—
P/S (TTM)7.8x
Div yield—
Key dataNov 4, 2026
Open
$1.81
From 52W high
−50.53%
Volume
7361.00
Market cap
$9.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.2x
P/E (TTM)
—
RSI (14)
29.4
MomentumView details →
1D Return
−2.09%
YTD Return
−32.42%
SummaryUpdated Jun 1, 2026
BioLineRx Ltd. (NASDAQ:BLRX) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, Israel. The company has undergone a significant strategic transformation from a development-focused biotech to a hybrid commercial and development organization. Following FDA approval of its lead drug APHEXDA in September 2023, BioLineRx successfully launched its first commercial product while simultaneously executing a major licensing deal with Ayrmid Pharma in 2024 that fundamentally reshaped its business model and financial profile.
Similar companies
Latest newsMore news →
BioLineRx Ltd. and Hemispherian AS presented preclinical data at ESMO 2026 showing synergy between GLIX1 and multiple PARP inhibitors in HR-proficient ovarian cancer models.12d agoBioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.65d ago